|
1
|
Liu Z, Tang H, Zhang W, Wang J, Wan L, Li X, Ji Y, Kong N, Zhang Y, Wang J, Fan Z, Guo Q. Coupling of serum CK20 and hyper-methylated CLIP4 as promising biomarker for colorectal cancer diagnosis: from bioinformatics screening to clinical validation. Aging (Albany NY) 2021; 13:26161-26179. [PMID: 34965217 PMCID: PMC8751608 DOI: 10.18632/aging.203804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 12/13/2021] [Indexed: 11/25/2022]
Abstract
Colorectal cancer (CRC) is one of the most common and lethal malignancies. The identification of minimally invasive and precise biomarkers is an urgent need for the early diagnosis of CRC. Through bioinformatics analysis of 395 CRC tissues and 63 CRC cell lines, CK18, CK20, de-methylated HPDL and hyper-methylated CLIP4 were identified as candidate serum biomarkers. Then, a training cohort consisting of 60 CRC, 30 colorectal adenomas (CA) and 33 healthy controls and a validation cohort consisting of 60 CRC, 30 CA and 30 healthy controls were enrolled. In the training cohort, enzyme-linked immunosorbent assay (ELISA) showed that CK18 and CK20 were all significantly higher in CRC and CA. CK18 diagnosed CRC with 46.67% sensitivity and 87.3% specificity; CK20 diagnosed CRC with 28.33% sensitivity and 90.47% specificity. Methylation-specific PCR (MSP) indicated that de-methylated HPDL and hyper-methylated CLIP4 were significantly detected in CRC and CA. De-methylated HPDL diagnosed CRC with 36.67% sensitivity and 93.65% specificity and hyper-methylated CLIP4 with 73.33% sensitivity and 84.13% specificity. Random combined analysis suggested that CK20/hyper-methylated CLIP4 diagnosed CRC with 91.67% sensitivity and 82.54% specificity. In the validation cohort, CK20 diagnosed CRC with 36.7% sensitivity and 88.3% specificity and hyper-methylated CLIP4 with 80% sensitivity and 85% specificity. CK20/hyper-methylated CLIP4 diagnosed CRC with 95% sensitivity and 81.7% specificity. Compared with serum biomarkers reported before, CK20/hyper-methylated CLIP4 possessed the potential to be a new effective and precise diagnostic biomarker for CRC.
Collapse
Affiliation(s)
- Zhongjian Liu
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Hui Tang
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Wen Zhang
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Jinli Wang
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Lilan Wan
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Xisha Li
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| | - Yuping Ji
- Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming, China
| | - Na Kong
- Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming, China
| | - Yanfang Zhang
- Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming, China
| | - Jiangang Wang
- Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming, China
| | - Zhang Fan
- Department of Gastroenterology, The Third People's Hospital of Yunnan Province, Kunming, China
| | - Qiang Guo
- Department of Gastroenterology, The First People's Hospital of Yunnan Province, Kunming, China.,The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
| |
Collapse
|
|
2
|
Xu QW, Zhao W, Wang Y, Sartor MA, Han DM, Deng J, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao HM, Yin YH, Chen WF, Zhang Y, Wang XS. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res 2012; 72:6351-61. [PMID: 23135912 PMCID: PMC3525759 DOI: 10.1158/0008-5472.can-12-1656] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Tumor-specific antigens (TSA) are central elements in the immune control of cancers. To systematically explore the TSA genome, we developed a computational technology called heterogeneous expression profile analysis (HEPA), which can identify genes relatively uniquely expressed in cancer cells in contrast to normal somatic tissues. Rating human genes by their HEPA score enriched for clinically useful TSA genes, nominating candidate targets whose tumor-specific expression was verified by reverse transcription PCR (RT-PCR). Coupled with HEPA, we designed a novel assay termed protein A/G-based reverse serological evaluation (PARSE) for quick detection of serum autoantibodies against an array of putative TSA genes. Remarkably, highly tumor-specific autoantibody responses against seven candidate targets were detected in 4% to 11% of patients, resulting in distinctive autoantibody signatures in lung and stomach cancers. Interrogation of a larger cohort of 149 patients and 123 healthy individuals validated the predictive value of the autoantibody signature for lung cancer. Together, our results establish an integrated technology to uncover a cancer-specific antigen genome offering a reservoir of novel immunologic and clinical targets.
Collapse
Affiliation(s)
- Qing-Wen Xu
- Department of Immunology, Peking University Health Science Center, Beijing 100191, China
| | - Wei Zhao
- Department of Immunology, Peking University Health Science Center, Beijing 100191, China
| | - Yue Wang
- Lester & Sue Smith Breast Center and Dan L, Duncan Cancer Center, Baylor College of Medicine, CCMB, University of Michigan, MI, 48109, USA
| | - Maureen A. Sartor
- National Center for Integrative Biomedical Informatics, CCMB, University of Michigan, MI, 48109, USA
| | - Dong-Mei Han
- Department of Hematology, PLA Air Force General Hospital, Beijing 100036, China
| | - Jixin Deng
- Human Genome Sequencing Center, Baylor College of Medicine
| | - Rakesh Ponnala
- Lester & Sue Smith Breast Center and Dan L, Duncan Cancer Center, Baylor College of Medicine, CCMB, University of Michigan, MI, 48109, USA
| | - Jiang-Ying Yang
- Department of Clinical Laboratory, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
| | - Qing-Yun Zhang
- Department of Clinical Laboratory, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
| | - Guo-Qing Liao
- Department of Oncology, PLA 309 Hospital, Beijing, China
| | - Yi-Mei Qu
- Department of Oncology, PLA 309 Hospital, Beijing, China
| | - Lu Li
- Department of Cardiothoracic Surgery, the 306th Hospital of PLA, Beijing, China
| | - Fang-Fang Liu
- Department of Pathology, Peking University People’s Hospital, Beijing 100044, China
| | - Hong-Mei Zhao
- Department of Surgery, Peking University Third Hospital, Beijing 100191, China
| | - Yan-Hui Yin
- Department of Immunology, Peking University Health Science Center, Beijing 100191, China
| | - Wei-Feng Chen
- Department of Immunology, Peking University Health Science Center, Beijing 100191, China
| | - Yu Zhang
- Department of Immunology, Peking University Health Science Center, Beijing 100191, China
| | - Xiao-Song Wang
- Lester & Sue Smith Breast Center and Dan L, Duncan Cancer Center, Baylor College of Medicine, CCMB, University of Michigan, MI, 48109, USA
| |
Collapse
|
|
3
|
Li GS, Yan DG, Zhang RY, Zhen YH, Ji QH, Cheng HY. Correlation between expression of CK20 mRNA in peripheral blood and clinicopathological features and prognosis in patients with colorectal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20:1993-1997. [DOI: 10.11569/wcjd.v20.i21.1993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the clinical significance of cytokeratin 20 (CK20) mRNA expression in peripheral venous blood of patients with colorectal carcinoma.
METHODS: The expression of CK20 mRNA was detected by RT-PCR in peripheral venous blood samples from 20 healthy volunteers, 10 patients with colorectal polyps, and 61 patients with colorectal cancer.
RESULTS: The positive rate of CK20 mRNA in peripheral venous blood of patients with colorectal cancer was 41.0% (25/61). CK20 mRNA expression in peripheral venous blood was associated with TNM stage, local lymph node metastasis, distant metastasis, and depth of invasion (all P < 0.05). The expression of CK20 mRNA was not detected in peripheral venous blood of healthy volunteers and patients with colorectal polyps. Seventeen cases died during the follow-up period, of whom 10 had positive expression of CK20 in peripheral blood.
CONCLUSION: CK20 is a specific marker for blood micrometastasis of colorectal cancer. The expression of CK20 mRNA in the blood of patients with colorectal cancer is related with the invasion and metastasis of colorectal cancer. Detection of CK20 mRNA in peripheral blood seems to be of relevance for prognosis in colorectal cancer.
Collapse
|